Harmony Biosciences

CNS diseases


HBM contact: Dr Andreas Wicki, Dr Emil Bujak

Company status: private

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, Harmony partnered with Bioprojet SCR to develop, register and market the drug, pitolisant, for the potential treatment of adult narcolepsy. Pitolisant, a histamine H3- receptor antagonist/inverse agonist, is approved by European Medicines Agency under the brand name Wakix.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171